An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.

ABSTRACT:

Background & aims

Quantitative analysis of computed tomography (CT) scans of patients with metastatic colorectal cancer (mCRC) can identify imaging signatures that predict overall survival (OS).

Methods

We retrospectively analysed CT images from 1584 mCRC patients on two phase III trials evaluating FOLFOX ± panitumumab (n = 331, 350) and FOLFIRI ± aflibercept (n = 437, 466). In the training set (n = 720), an algorithm was trained to predict OS landmarked from month 2; the output was a signature value on a scale from 0 to 1 (most to least favourable predicted OS). In the validation set (n = 864), hazard ratios (HRs) evaluated the association of the signature with OS using RECIST1.1 as a benchmark of comparison.

Results

In the training set, the selected signature combin

SUBMITTER: Dercle L 

PROVIDER: S-EPMC10018811 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature